Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 134, Issue 3, Pages 530-544Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2014.03.007
Keywords
Mast cell; basophil; mediator; receptor; signaling protein; survival protein; drug; therapy
Categories
Funding
- COST Action BM1007 Mast cells and Basophils: targets for innovative therapies
- Cancer Center of Eastern Finland
- VTR funding of Kuopio University Hospital
- Israel Science Foundation [213/05]
- MAARS (Microbes in Allergy and Autoimmunity Related to the Skin) EU 7th framework [HEALTH-F2-2011-261366]
- Aimwell Charitable Trust (London, United Kingdom)
- Ministry of Education of the Czech Republic [COST CZ LD12073]
- Czech Science foundation [14-00703S, 14-09807S, P302/12/G101]
- Institute of Molecular Genetics ASCR [RVO 68378050]
- Faculty of Science, Charles University, Prague
- French National Research Agency [ANR-12-ISV3-0006-01]
- Investissements d'Avenir programme [ANR-11-IDEX-0005-02]
- Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX
Ask authors/readers for more resources
Mast cells and basophils (MCs/Bs) play a crucial role in type I allergy, as well as in innate and adaptive immune responses. These cells mediate their actions through soluble mediators, some of which are targeted therapeutically by, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists. Recently, considerable progress has been made in developing new drugs that target additional MC/B mediators or receptors, such as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, prostaglandin D-2, and proinflammatory cytokines. Mediator production can be abrogated by the use of inhibitors directed against key intracellular enzymes, some of which have been used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, Bruton tyrosine kinase, and the protein tyrosine kinase KIT). Reduced MC/B function can also be achieved by enhancing Src homology 2 domain-containing inositol 5' phosphatase 1 activity or by blocking sphingosine-1-phosphate. Therapeutic interventions in mast cell-associated diseases potentially include drugs that either block ion channels and adhesion molecules or antagonize antiapoptotic effects on B-cell lymphoma 2 family members. MCs/Bs express high-affinity IgE receptors, and blocking their interactions with IgE has been a prime goal in antiallergic therapy. Surface-activating receptors, such as CD48 and thymic stromal lymphopoietin receptors, as well as inhibitory receptors, such as CD300a, Fc gamma RIIb, and endocannabinoid receptors, hold promising therapeutic possibilities based on preclinical studies. The inhibition of activating receptors might help prevent allergic reactions from developing, although most of the candidate drugs are not sufficiently cell specific. In this review recent advances in the development of novel therapeutics toward different molecules of MCs/Bs are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available